# Aravax: Research, Melbourne, Australia

> Aravax: Aravax is a clinical-stage biotechnology company focused on developing innovative immunotherapies for food allergies. Based in Melbourne, Australia.

Source: https://millionrounds.com/startup/aravax (Millionrounds; every figure on the page links to its filing or article)

Australia · [Research startup](https://millionrounds.com/companies)

# Aravax

Aravax is a clinical-stage biotechnology company focused on developing innovative immunotherapies for food allergies.

Funding reported Last round: Series B

Research Melbourne, Australia

Follow Aravax and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Faravax)

Company summary

- **Founded:** 2015 11 years old
- **Team:** 20 11 to 50 people
- **Funding reported:** 42.2M as listed, currency not stated
- **Last round:** Series B Jan 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Aravax has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Aravax

Aravax is a clinical-stage biotechnology company focused on developing innovative immunotherapies for food allergies.

Founded in May 2015, the company is based in Melbourne, Australia, and has operations in the UK, USA, and Europe. Aravax is privately held and employs a dedicated team of approximately 11 to 50 staff members. The company is supported by a group of prominent investors, including the Novartis Venture Fund and Brandon Capital Partners. The core service of Aravax involves the design and clinical testing of peptide-based immunotherapies that aim to retrain the immune system to tolerate specific food allergens, such as peanuts. Their lead product, PVX108, is currently in Phase 2 trials, targeting peanut allergies in children and adolescents. Aravax is also expanding its pipeline to address additional food allergies, leveraging its proprietary technology platform to create safe and effective treatments for a broader range of allergens.

## What company datasets say Aravax raised

Funding, as reported

Reported in all **42.2M** in the source's currency

Rounds **3**

Last round **Series B**

Last round size **42M**

Last round date **Jan 2024**

Investors listed **8**

## The company, in detail

What they build

Known for

health care allergy treatment immunological markers biotechnology research allergy-specific therapeutics allergy biotech company healthcare food allergy research immune system modulation peptide immunotherapy allergy treatment pipeline immune system retraining allergen-specific peptides phase 2 clinical trials allergy immunotherapy allergen tolerance allergy immunology

Built with from their website

Microsoft Exchange Microsoft 365 Outlook Microsoft 365 Apps & Services Microsoft Email Providers Microsoft Exchange Online

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** Victoria
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/aravax)

## Research in Australia

Startups like it

- [**PolyActiva** Melbourne · founded 2010 *Raised*](https://millionrounds.com/company/polyactiva)
- [**Ferronova** Adelaide · founded 2016 *Raised*](https://millionrounds.com/company/ferronova)
- [**Nbryo** Brisbane · founded 2020 *Raised*](https://millionrounds.com/company/nbryo)
- [**Fremantle Seaweed** Perth *Raised*](https://millionrounds.com/company/fremantle-seaweed)
- [**Bovotica** Brisbane · founded 2023 *Raised*](https://millionrounds.com/company/bovotica)
- [**Bower** Byron Bay · founded 2025 *Raised*](https://millionrounds.com/company/bower)
- [**Levur** Sydney · founded 2023 *Raised*](https://millionrounds.com/company/levur)
- [**Cell Bauhaus** Melbourne · founded 2023 *Raised*](https://millionrounds.com/company/cell-bauhaus)

## Is this your company?

Add your raise, your deck and your story, and put Aravax in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)